Abstract
The potent tropane analog, WF-23 [2β-propanoyl-3β-(2-naphthyl) tropane], blocks dopamine, serotonin, and norepinephrine transporters with high affinity in vitro and blocks transporters for at least 2 days following a single in vivo administration. Previous studies demonstrated desensitization of monoamine receptor-coupled G-proteins in brain following chronic treatment of rats with WF-23. The current study sought to determine the time course of this desensitization and the behavioral effects of receptor desensitization. Rats were treated with 1 mg/kg WF-23 and injected i.p. every 48 h for 1 to 21 days. Receptor activation of G-proteins was determined by guanosine 5′-O-(3-[35S]thiotriphosphate) ([35S]GTPγS) binding in brain sections for monoamine receptors, as well as μ opioid receptors as a nonmonoamine receptor control. Chronic treatment with WF-23 produced significant reductions in D2, 5-hydroxytryptamine 1A, and α2-adrenergic receptor-stimulated [35S]GTPγS binding; however, the time course of desensitization varied with different receptors. There was no effect of WF-23 treatment on μ opioid-stimulated [35S]GTPγS binding at any time point. Consistent with previous studies, there was no effect of WF-23 treatment on D2 receptor binding, as determined by [3H]spiperone autoradiography. Locomotor activity was significantly increased for up to 48 h following acute administration of WF-23, demonstrated by increased photocell beam interruptions. WF-23-induced increases in locomotor activity occurred following repeated administration, as above, for up to 7 days. Following 7 days of treatment, there was a significant decrease in WF-23-increased locomotor activity. This reduction occurred at the same time point as the decrease in D2 receptor/G-protein coupling, suggesting a role of D2 desensitization in producing tolerance to WF-23-mediated behavior.
Footnotes
-
This work was supported in part by DA-06634 (S.R.C., H.M.L.D.), DA-07246 (K.A.O.), and DA-16840 (K.A.O.) from the National Institute on Drug Abuse.
-
doi:10.1124/jpet.104.078451.
-
ABBREVIATIONS: DAT, dopamine transporter; SERT, serotonin transporter; NET, norepinephrine transporter; WF-23, 2β-propanoyl-3β-(2-naphthyl) tropane; [35S]GTPγS, guanosine 5′-O-(3-[35S]thiotriphosphate); 5-HT1A, 5-hydroxytryptamine 1A; DAMGO, [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin; NPA, R(–)-propylnorapomorphine; 8-OH-DPAT, 8-hydroxy-2-dipropylaminotetralin; [125I]RTI-55, 3β-(4-[125I]iodophenyl)-tropane-2-carboxylic acid methyl ester.
- Received September 28, 2004.
- Accepted January 10, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|